Location History:
- Keelung, TW (2002 - 2008)
- Taipei, TW (2001 - 2022)
- Hsinchu County, TW (2023)
Company Filing History:
18 out of 34 
2 out of 135 
1 out of 1,820 
Years Active: 2001-2023
Title: **Michael Chen: Innovator in Antibody Development**
Introduction
Michael Chen, a prominent inventor based in Keelung, Taiwan, has made significant strides in the field of biomedical innovations. With a remarkable portfolio of 23 patents, he is recognized for his contributions to antibody development and cancer treatment technologies.
Latest Patents
Among his latest patented inventions, the "Anti-tumor/anti-tumor associated fibroblast/anti-hapten trispecific antibodies and use thereof" stands out. This innovative trispecific antibody (TsAb) is designed to target both tumor cells and tumor-associated fibroblasts (TAFs), allowing for the simultaneous administration of various hapten-conjugated anti-cancer drugs. The dual-targeting capability enhances the effectiveness of the treatment by enabling targeted delivery of nanocarrier drugs, small molecule drugs, protein drugs, and radioactive drugs directly to the affected areas.
Another noteworthy patent is the "Tandemly repeated antibody-binding protein and its applications." This invention features a tandemly repeated protein that can improve the sensitivity and detection limits in immunoassays. By expressing the antibody binding protein on cell membranes, this technology can significantly enhance diagnostic capabilities in the medical field.
Career Highlights
Michael Chen has worked with notable organizations including Surtec Industries, Inc. and Taipei Medical University, where he has contributed his expertise in antibody development and innovative solutions in healthcare. His dedication to advancing medical technologies has positioned him as a leading figure in his field.
Collaborations
Throughout his career, Michael has collaborated with talented individuals such as Kuo-Hsiang Chuang and Yi-Jou Chen. These partnerships have fostered the development of groundbreaking solutions in the realm of cancer treatment and diagnostics.
Conclusion
In conclusion, Michael Chen's contributions to innovation in the fields of antibody development and cancer therapies underscore his status as a distinguished inventor. With a strong patent portfolio and collaborative efforts, he continues to push the boundaries of medical technology, promising enhanced treatment options for patients worldwide.